Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: A study protocol.
Takeshi NakaharaKenji IzuharaDaisuke OnozukaSatoshi NunomuraRisa Tamagawa-MineokaKoji MasudaSusumu IchiyamaHidehisa SaekiYudai KabataRiichiro AbeMamitaro OhtsukiKoji KamiyaTatsuro OkanoTomomitsu MiyagakiYozo IshiujiAkihiko AsahinaHiroshi KawasakiKeiji TaneseHiroshi MitsuiTatsuyoshi KawamuraTakuya TakeichiMasashi AkiyamaEmi NishidaAkimichi MoritaKyoko TonomuraYukinobu NakagawaKoji SugawaraChiharu TateishiYoko KataokaRai FujimotoSakae KanekoEishin MoritaAkio TanakaMichihiro HideNatsuko AokiShigetoshi SanoHaruna Matsuda-HiroseYutaka HatanoMotoi TakenakaHiroyuki MurotaNorito KatohMasutaka FuruePublished in: Medicine (2020)
This is the first clinical trial to explore the biomarkers, including potential proteomic markers, most strongly associated with improvement in EASI in patients with moderate-to-severe AD treated with dupilumab for 16 weeks (B-PAD study). A limitation is that we will only enroll Japanese patients.